We sent an email to employers (upstate / downstate) last week outlining Prescription Drug Data Collection (RxDC) reporting requirements that begin December 27, 2022.
The RxDC reporting provision of the Consolidated Appropriations Act (CAA) requires reports on drug utilization and spending trends to be submitted to U.S. Department of Health and Human Services beginning December 27, 2022.
- For ASO and Fully Insured clients, we will submit the aggregated data by market segment on behalf of our clients, for the benefits we administer and maintain, including pharmacy data for clients that have integrated pharmacy with IngenioRx.
- For JAA and MCS clients, the JAA Payor, or Client has the most current and accurate information required to support the reporting. They would need to submit the report.
We are proceeding with these reports as required by the Interim Final Rule issued in November 2021, including instructions for this reporting, with revisions published on June 28, 2022. The file layouts for each report are included in the appendix of the RxDC Reporting Instructions. We do expect additional regulatory guidance regarding these provisions. We will continue to monitor regulatory activity and advise clients of any updates.
Please contact your sales representative for more information.